Source comparison
MK-677 Ghrelin Receptor Oral Mechanism: Comparison
MK-677 GHSR1a (selective agonist) Oral 60–70% Preserves pulsatility, increases amplitude Moderate increase (20–30% of users) 4–6 hours plasma, 24-hour functional duration Most practical for long-term protocols. Oral dosing, no axis suppression, sustained IGF-1
This comparison does not assign a generated winner or score.
- MK-677
- GHSR1a (selective agonist)
- Oral
- 60–70%
- Preserves pulsatility, increases amplitude
- Moderate increase (20–30% of users)
- 4–6 hours plasma, 24-hour functional duration
- Most practical for long-term protocols. Oral dosing, no axis suppression, sustained IGF-1 elevation
- GHRP-2
- GHSR1a (peptide agonist)
- Subcutaneous injection
- N/A (peptide degraded orally)
- Preserves pulsatility, dose-dependent amplitude
- Minimal
- <30 minutes
- Potent but requires 2–3 daily injections. Impractical for extended studies
- GHRP-6
- GHSR1a + orexigenic pathways
- Preserves pulsatility
- Strong appetite stimulation
- Highest appetite stimulation. Useful for cachexia models but confounding for metabolic studies
- Exogenous GH
- GH receptors (peripheral tissues)
- N/A
- Sustained elevation, suppresses endogenous pulses
- None (direct)
- 2–3 hours
- Suppresses natural GH axis. Requires cycling, causes receptor desensitisation